Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Accounts Payables of $4.3 million for Q1 2026, up 3.98% year-over-year from $4.1 million in Q1 2025, and down 18.52% quarter-over-quarter from $5.3 million in Q4 2025.
Protalix BioTherapeutics (PLX) Accounts Payables (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $4.3 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 3.98% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 3.98% YoY), while the FY2025 annual figure was $5.3 million, up 16.02% from the prior year.
- Accounts Payables for Q1 2026 stood at $4.3 million, down from $5.3 million in the prior quarter.
- The five-year high for Accounts Payables was $19.6 million in Q3 2024, with the low at $3.1 million in Q3 2023.
- The 5-year median for Accounts Payables is $5.9 million (2022), against an average of $8.9 million.
- Peak annual rise in Accounts Payables reached 528.68% in 2024, while the deepest fall reached 76.65% in 2024.
- Protalix BioTherapeutics' Accounts Payables stood at $5.9 million in 2022, then decreased by 26.31% to $4.3 million in 2023, then gained by 4.93% to $4.5 million in 2024, then climbed by 16.02% to $5.3 million in 2025, then retreated by 18.52% to $4.3 million in 2026.
- Business Quant data shows PLX's Accounts Payables at $4.3 million in Q1 2026, $5.3 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 35.57 Mn |
| 10 | Protalix BioTherapeutics | 193.97 Mn | 153.31 Mn | 12.13 Mn | 6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.51 Mn |
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 5.26 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 6.69 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Dec 31, 2024 | 4.53 Mn |
| Sep 30, 2024 | 19.58 Mn |
| Jun 30, 2024 | 19.34 Mn |
| Mar 31, 2024 | 3.15 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 3.11 Mn |
| Jun 30, 2023 | 18.55 Mn |
| Mar 31, 2023 | 13.47 Mn |
| Dec 31, 2022 | 5.86 Mn |
| Sep 30, 2022 | 12.87 Mn |
| Jun 30, 2022 | 12.66 Mn |
| Mar 31, 2022 | 7.87 Mn |
| Dec 31, 2021 | 6.99 Mn |
| Sep 30, 2021 | 8.44 Mn |